Main
Multiple myeloma, MM
MULTIPLE MYELOMA
Multiple myeloma (MM) is the second most common hematologic malignancyAutologous stem cell transplantation in MM has been shown to improve event-free survival and OS compared with conventional chemotherapy alone in previously untreated standard-risk MMGranulocyte colony-stimulating factor (G-CSF) is widely considered the standard agent for PB HSPC mobilization. Nevertheless, despite the use of G-CSF in mobilization of HSPCs to the PB and after multiple days of apheresis, 40–50% of patients with MM remain unable to collect optimal numbers of HSPCs for ASCTThe interaction between CXCL12 and its receptor, CXCR4, is critically involved in the retention of HSPCs within the bone marrow and blockade of CXCR4 mobilizes HSPCs to PBMotixafortide (BL-8040) is a selective cyclic-peptide inhibitor of CXCR4 with high affinity (Ki, 0.32 nM), long receptor occupancy and extended clinical activity (>48 h)Therefore, this phase 3 study (GENESIS) was designed to compare the safety and efficacy of motixafortide + G-CSF versus placebo + G-CSF in patients with MM undergoing HSPC mobilization before ASCT (